<DOC>
	<DOCNO>NCT03038256</DOCNO>
	<brief_summary>The purpose study evaluate effect 4 Cycles XELOX Pre- post-a delayed TME compare 8 Cycles XELOX post-a Regular Timing TME Continuous Infusion Fluorouracil Long-term Radiotherapy patient high-risk rectal cancer define MRI .</brief_summary>
	<brief_title>Effect 4 Cycles XELOX Pre- post-a Delayed TME Compared With 8 Cycles XELOX post-a Regular Timing TME Patients With High Risk Rectal Cancer ( EXPLORE )</brief_title>
	<detailed_description>This randomise , multi-centers , open-labeled , phase III study . Delivering systemic chemotherapy continuous infusion Fluorouracil long-term radiotherapy ( CRT ) total mesorectal excision ( TME ) surgery would effectively improve local control rate improve metastases-free survival rate . The investigator attempt investigate effect disease free survival deliver 4cycles XELOX CRT TME lengthen interval radiation surgery . In study , participant high risk deep infiltration , extramural vessel invasion , circumferential resection margin involvement , lymph node metastasis et al . recruit . The participant randomize ( 1:1 ratio ) control intervention arm . The participant control arm receive best current practice TME 6-8 week continuous infusion Fluorouracil long-term radiotherapy 8cycles XELOX standard adjuvant chemotherapy . The participant intervention arm receive 4cycles XELOX pre- post- delay TME continuous infusion Fluorouracil long-term radiotherapy .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Age 1875 year ; 2 . Histologically confirm adenocarcinoma ; 3 . The rectal adenocarcinoma 012cm anal margin MRI and/or rigid sigmoidoscopy ; 4 . High risk rectal cancer define highresolution MRI : tumor invasion 5mm beyond muscularis propria , EMVIpositive , CRM unsafe , low rectal cancer invades intersphincteric space lie within 1 mm levator muscle , invade external anal sphincter within 1 mm beyond levator muscle without invade adjacent structure ; 5 . Eastern Collaborative Oncology Group performance status score 0 2 6 . Able willing give inform consent participate . 1 . Received preoperative chemoradiotherapy rectal cancer recruitment study ; 2 . Have metastatic disease ( include resectable liver metastasis ) ; 3 . Other malignancy , nonadenocarcinoma rectal malignancy rectal malignancy basis inflammatory bowel disease ; 4 . Emergency surgery due bowel obstruction , perforation , bleeding , etc . ; 5 . Abnormality capecitabine absorption due gastrointestinal disease e.g . short bowel syndromle , inflammation bowel disease , et al . ; 6 . Unresectable concurrent intestinal lesion ; 7 . Concurrent sever infection； 8 . Cardiac Disease：uncontrolled symptomatic cardiac angina，or uncontrolled arrhythmias hypertension , severe congestive heart failure grade II base New York Heart Association ( NYHA ) ; myocardial infarction within past 12 month 9 . Peripheral neuropathy grade 1 accord National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ; version 3·0 ) 10 . Bone marrow , liver kidney function abnormal e.g. , WBC ≤ 1.5 × 109 / L ; platelet ≤ 100 × 109 / L ; Haemoglobin ≤ 80 g/L ; Bilirubin &gt; 1.5 time upper limit ; aspartate aminotransferase alanine aminotransferase &gt; 2.5 time upper limit ; creatinine &gt; 1.5 time upper limit ; 11 . Pregnant lactating woman ; 12 . Life prediction le 3 month , severe disease ; 13 . Contraindication MRI ; e.g . nonMR compatible hip prosthesis , cardiac pacemaker ; 14 . Contraindication standard chemotherapy include drug interaction glomerular filtration rate &lt; 50 mL/min baseline ; 15 . Participators recruit clinical trial within three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High Risk Rectal Cancer</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Delayed total mesorectal excision</keyword>
</DOC>